The concern of generic rivalry has repeatedly loomed above copyright’s famous drug, Viagra, triggering questions about the prospects of related medicinal holdings. While first periods saw significant profits, the patent end has created the path for cheaper copies, possibly reducing profitability and posing a real risk for stakeholders looking for